Placebo News and Research

RSS

Cerenis' Phase IIb CHI-SQUARE study fails to meet primary endpoint in post-ACS patients

Cerenis Therapeutics, the biopharmaceutical company, today announced that its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression?) study did not reach its primary endpoint in post-Acute Coronary Syndrome patients.

2 Jan 2014

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Amgen and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).

2 Jan 2014

Study: Alpha tocepherol, fat-soluble vitamin E, antioxidant may slow functional decline in AD patients

Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans. These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends.

1 Jan 2014

Binge drinking during pregnancy can lead to fetal alcohol syndrome

Recent data shows that more than 500,000 women in the U.S. report drinking during pregnancy, with about 20 percent of this population admitting to binge drinking.

31 Dec 2013

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Genzyme, a Sanofi company, announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.

30 Dec 2013

Nonsteroidal anti-inflammatory agent delays neuropathy progression, preserves quality of life

Among patients with familial amyloid polyneuropathy, a lethal, genetic neurodegenerative disease, use of the nonsteroidal anti-inflammatory agent diflunisal compared with placebo for 2 years reduced the rate of progression in neurological impairment and preserved quality of life, according to a study appearing in the December 25 issue of JAMA.

27 Dec 2013

FIDELITY project compares surgical treatment of degenerative meniscal tears to placebo surgery

The Finnish Degenerative Meniscal Lesion Study (FIDELITY) compared surgical treatment of degenerative meniscal tears to placebo surgery.

27 Dec 2013

Antidepressant nortriptyline does not improve overall symptoms in patients with idiopathic gastroparesis

Among patients with idiopathic (of unknown cause) gastroparesis, use of the antidepressant nortriptyline compared with placebo for 15 weeks did not result in improvement in overall symptoms, according to a study appearing in the December 25 issue of JAMA.

25 Dec 2013

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine and Boston Medical Center demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced neurological decline and preserved the quality of life in patients with familial transthyretin amyloidosis. Diflunisal is an inexpensive and safe medication marketed over the past 40 years for arthritis and pain.

25 Dec 2013

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Synergy Pharmaceuticals Inc. today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation.

24 Dec 2013

Study: Antidepressants not effective for bipolar disorder treatment

The use of antidepressants in the treatment of bipolar disorder remains controversial. Some studies and treatment guidelines suggest that antidepressant treatment for bipolar disorder may have the potential to increase the manic switch, while others recommend short-term antidepressant treatment and early discontinuation.

24 Dec 2013

Duration of common pediatric respiratory infections estimated

An international research team has systematically reviewed the literature to formulate up-to-date estimates of the duration of common childhood respiratory tract infections.

24 Dec 2013

Inosine drug raises blood and cerebrospinal fluid urate levels in Parkinson disease patients

The drug inosine appears to be a safe and effective way to raise blood and cerebrospinal fluid urate levels in patients with early Parkinson disease, suggesting it may be a potential strategy to slow the disability progression of the degenerative neurological disorder, according to a report published by JAMA Neurology, a JAMA Network publication.

23 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

Study supports use of two drugs for treating children with aggression and disruptive behavior

Prescribing both a stimulant and an antipsychotic drug to children with physical aggression and attention-deficit/hyperactivity disorder, along with teaching parents to use behavior management techniques, reduces aggressive and serious behavioral problems in the children, according to a study conducted by researchers at The Ohio State University Wexner Medical Center.

22 Dec 2013

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity.

21 Dec 2013

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52.

20 Dec 2013

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

FibroGen, Inc., announced today that patient enrollment has started in a new Phase 2 clinical study of FG-3019 in patients who suffer from idiopathic pulmonary fibrosis.

20 Dec 2013

Researchers reveal how metabolic system breaks down in obesity

Researchers at University of Michigan have illuminated an aspect of how the metabolic system breaks down in obesity. The findings provide additional evidence that a drug entering clinical trials at the university could reverse obesity, Type 2 diabetes and fatty liver disease in humans.

20 Dec 2013

Placebo News and Research

Cerenis' Phase IIb CHI-SQUARE study fails to meet primary endpoint in post-ACS patients

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Study: Alpha tocepherol, fat-soluble vitamin E, antioxidant may slow functional decline in AD patients

Binge drinking during pregnancy can lead to fetal alcohol syndrome

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Nonsteroidal anti-inflammatory agent delays neuropathy progression, preserves quality of life

FIDELITY project compares surgical treatment of degenerative meniscal tears to placebo surgery

Antidepressant nortriptyline does not improve overall symptoms in patients with idiopathic gastroparesis

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Study: Antidepressants not effective for bipolar disorder treatment

Duration of common pediatric respiratory infections estimated

Inosine drug raises blood and cerebrospinal fluid urate levels in Parkinson disease patients

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Study supports use of two drugs for treating children with aggression and disruptive behavior

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

Researchers reveal how metabolic system breaks down in obesity

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News